PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks

AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alir...

Descripción completa

Detalles Bibliográficos
Autores principales: Hollstein, Tim, Kassner, Ursula, Grenkowitz, Thomas, Schumann, Friederike, Bobbert, Thomas, Steinhagen-Thiessen, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838077/
https://www.ncbi.nlm.nih.gov/pubmed/32514867
http://dx.doi.org/10.1007/s40256-020-00411-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838077/
https://www.ncbi.nlm.nih.gov/pubmed/32514867
http://dx.doi.org/10.1007/s40256-020-00411-3

Ejemplares similares